Please use this identifier to cite or link to this item:
Title: Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1
Authors: Wang, L 
Chan, C.E.L
Wong, A.L.-A 
Wong, F.C
Lim, S.W 
Chinnathambi, A
Alharbi, S.A
Lee, L.S.-U 
Soo, R 
Yong, W.P 
Lee, S.C 
Ho, P.C.-L 
Sethi, G 
Goh, B.C 
Keywords: belinostat
firtecan glucuronide
glucuronosyltransferase 1A1
controlled study
drug glucuronidation
enzyme inactivation
enzyme inhibition
human cell
in vitro study
incubation time
limit of quantitation
liquid chromatography-mass spectrometry
liver microsome
measurement accuracy
measurement precision
Issue Date: 2017
Citation: Wang, L, Chan, C.E.L, Wong, A.L.-A, Wong, F.C, Lim, S.W, Chinnathambi, A, Alharbi, S.A, Lee, L.S.-U, Soo, R, Yong, W.P, Lee, S.C, Ho, P.C.-L, Sethi, G, Goh, B.C (2017). Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1. Oncotarget 8 (25) : 41572-41581. ScholarBank@NUS Repository.
Abstract: SN-38, the active metabolite of irinotecan, and histone deacetylase inhibitors (HDACis) such as belinostat, vorinostat and panobinostat, have all been shown to be deactivated by glucuronidation via UGTs. Since they all compete for UGTs for deactivation, we aimed to investigate the inhibitory effect of various HDACis on the glucuronidation of SN-38. This inhibitory effect was determined by measuring the formation rate of SN-38 glucuronide after SN-38 incubation with human recombinant UGT1A isoforms (1A1, 1A6, 1A7 and 1A9) and pooled human liver microsomes (HLM, wild type, UGT1A1*1*28 and UGT1A1*28*28 allelic variants), with and without HDACis. The data showed that belinostat at 100 and 200 ?mol/L inhibited SN-38 glucuronidation via UGT1A1 in a dose-dependent manner, causing significant decrease in Vmax and CLint (p < 0.05) from 12.60 to 1.95 pmol/min/mg and 21.59 to 4.20 ?L/min/mg protein respectively. Similarly, in HLMs, Vmax dropped from 41.13 to 10.54, 24.96 to 3.77 and 6.23 to 3.30 pmol/min/mg, and CLint reduced from 81.25 to 26.11, 29.22 to 6.10 and 5.40 to 1.34 ?L/min/mg protein for the respective wild type, heterozygous and homozygous variants. Interestingly, belinostat at 200 ?mol/L that is roughly equivalent to the average Cmax, 183 ?mol/L of belinostat at a dose of 1,400 mg/m2 given intravenously once per day on days 1 to 5 every 3 weeks, was able to inhibit both heterozygous and homozygous variants to same extents (~64%). This highlights the potential clinical significance, as a large proportion of patients could be at risk of developing severe toxicity if irinotecan is co-administered with belinostat. © Lingzhi Wang et al.
Source Title: Oncotarget
ISSN: 19492553
DOI: 10.18632/oncotarget.15017
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_18632_oncotarget_15017.pdf1.45 MBAdobe PDF




checked on Mar 3, 2021

Page view(s)

checked on Mar 5, 2021

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.